ClinicalTrials.gov
ClinicalTrials.gov Menu

Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00903890
Recruitment Status : Active, not recruiting
First Posted : May 19, 2009
Last Update Posted : January 9, 2018
Sponsor:
Information provided by (Responsible Party):
Louis Constine, University of Rochester

Brief Summary:
This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.

Condition or disease Intervention/treatment
Hodgkin Disease Lymphoma, Non-Hodgkin Other: Survey

Study Type : Observational
Actual Enrollment : 32 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma After Radiation Therapy/Anthracycline Chemotherapy
Study Start Date : August 2008
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Group/Cohort Intervention/treatment
A
Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
Other: Survey
Survey asking questions regarding the subjects cardiac and general health.



Primary Outcome Measures :
  1. Measure changes in Cardiac ejection fraction score [ Time Frame: Post Radiation Treatment ]
  2. Measure changes in perfusion imaging score on the radionuclide cardiac profusion scan [ Time Frame: Post Radiation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients previously treated at the University of Rochester Department of Radiation Oncology.
Criteria

Inclusion Criteria:

  • All patients with Hodgkin's Lymphoma and Non Hodgkin's lymphoma who underwent Radiation Therapy (RT) to either a mantle or modified mantle field with or without adriamycin at the Wilmot Cancer Center at the University of Rochester are eligible for the study.

Exclusion Criteria:

  • Any severe preexisting cardiac disease (e.g., arrhythmia, angina, coronary disease, myocardial infarction, or congestive heart failure) prior to diagnosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00903890


Locations
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
Investigators
Principal Investigator: Louis S Constine, MD University of Rochester

Responsible Party: Louis Constine, Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT00903890     History of Changes
Other Study ID Numbers: ULYM07056
First Posted: May 19, 2009    Key Record Dates
Last Update Posted: January 9, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases